Genprex (GNPX), an immunogene therapy development company has filed an IPO to sell up to $22.5 million of its common stock. The number of shares to be offered, as well as the price range for the offering, have not yet been determined.
Genprex is developing immunogene therapies to address the unmet medical needs of cancer patients.
Given the nascent stage of Genprex and the higher-than-usual regulatory risk of gene-based treatments, I’m generally skeptical of the wisdom of retail investing in such ultra-high-risk IPOs.
I’ll reserve my final opinion when we know more details about the IPO.